
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Trove at the National Library of Australia has information on archived TGA consultations and reviews.
Filters
Status
Categories
- Advertising (2) Apply Advertising filter
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Remove Biologicals filter Biologicals (2)
- Complementary medicines (7) Apply Complementary medicines filter
- Remove Cosmetics filter Cosmetics (0)
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Remove Listed medicines filter Listed medicines (2)
- Manufacturing (1) Apply Manufacturing filter
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Medical devices safety (1) Apply Medical devices safety filter
- Remove Medicinal cannabis filter Medicinal cannabis (1)
- Remove Medicines filter Medicines (2)
- Remove Medicines safety filter Medicines safety (1)
- OTC medicines (12) Apply OTC medicines filter
- Other therapeutic goods (1) Apply Other therapeutic goods filter
- Prescription medicines (7) Apply Prescription medicines filter
- Scheduling (56) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Therapeutic goods regulation (3) Apply Therapeutic goods regulation filter
- (-) Remove Medicinal cannabis filter Medicinal cannabis
- (-) Remove Listed medicines filter Listed medicines
- (-) Remove Biologicals filter Biologicals
- (-) Remove Cosmetics filter Cosmetics
- (-) Remove Medicines safety filter Medicines safety
- (-) Remove Medicines filter Medicines
Repurposing of medicines
Closed on 1 April 2022
Priority Review pathway for biologicals: feasibility, potential eligibility criteria and determination process
Closed on 28 March 2022
Improving access to medicine adverse event data - sponsor survey
Closed on 18 February 2022
Consultation on Extemporaneous Compounding of Emergency Medicines
Closed on 7 February 2022
Consultation on potential regulatory options for 'export only' biologicals
Closed on 20 December 2021
Proposed changes to the Permissible Ingredients Determination: Low-negligible risk changes 2021-22
Closed on 15 September 2021
Potential reforms to medicinal cannabis manufacturing, labelling and packaging requirement
Closed on 29 January 2021
Changes to permissible ingredients - Low-negligible risk
Closed on 11 October 2019